Beta Bionics, Inc. $BBNX Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) by 112.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 67,879 shares of the company’s stock after buying an additional 35,996 shares during the period. Quantinno Capital Management LP owned 0.15% of Beta Bionics worth $680,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Summit Securities Group LLC acquired a new stake in shares of Beta Bionics in the 4th quarter worth $52,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the last quarter. Strs Ohio purchased a new stake in shares of Beta Bionics in the first quarter valued at about $29,000. Legal & General Group Plc grew its holdings in shares of Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after purchasing an additional 2,639 shares during the period. Finally, CIBC Private Wealth Group LLC increased its position in Beta Bionics by 630,000.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 6,301 shares of the company’s stock worth $192,000 after purchasing an additional 6,300 shares during the last quarter.

Insider Transactions at Beta Bionics

In related news, insider Mark Hopman sold 5,329 shares of Beta Bionics stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $67,198.69. Following the completion of the sale, the insider owned 130,887 shares in the company, valued at approximately $1,650,485.07. This trade represents a 3.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,378 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $55,206.58. Following the completion of the sale, the insider directly owned 184,415 shares in the company, valued at approximately $2,325,473.15. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 40,351 shares of company stock worth $553,961. 5.30% of the stock is owned by company insiders.

Beta Bionics Trading Up 8.3%

Shares of BBNX opened at $19.02 on Wednesday. The company’s 50-day moving average price is $15.83 and its 200 day moving average price is $13.14. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The firm has a market cap of $855.71 million, a P/E ratio of -11.53 and a beta of 3.13.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The company had revenue of $32.01 million during the quarter. Equities research analysts forecast that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Analysts Set New Price Targets

BBNX has been the topic of a number of analyst reports. Leerink Partners reduced their target price on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Bank of America cut their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Stifel Nicolaus reduced their price target on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. Truist Financial lifted their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Beta Bionics in a research report on Friday, July 17th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $20.10.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.